INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Capricor Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 5, 2025, Capricor announced that the FDA confirmed its intent to hold an advisory committee meeting regarding the Biologics License Application for deramiocel, a treatment for Duchenne muscular dystrophy cardiomyopathy [3] - Following this announcement, Capricor's stock price dropped by $3.00 per share, representing a decline of 29.13%, closing at $7.30 per share on May 6, 2025 [4] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Capricor to discuss claims related to potential securities fraud [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [5]